BioVie Inc. (BIVI)
| Market Cap | 14.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.36M |
| Shares Out | 1.85M |
| EPS (ttm) | -16.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,326 |
| Open | 8.06 |
| Previous Close | 8.05 |
| Day's Range | 7.45 - 8.06 |
| 52-Week Range | 6.20 - 75.00 |
| Beta | 1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2025 |
About BIVI
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and chang... [Read more]
Financial Performance
Financial StatementsNews
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes p...
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurolog...
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurolog...
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurol...
Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI...
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior t...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior t...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). In...
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Inv...
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Inv...
Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Inv...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). I...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). I...
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). I...
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). I...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). I...
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitatin...
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitatin...
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitatin...
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitatin...
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks,...
BioVie Inc. Announces Closing of Public Offering
CARSON CITY, Nev., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitati...
Crude Oil Gains Over 1%; BioVie Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday.